United Kingdom Insulin Biosimilars Market Insight
United Kingdom Insulin Biosimilars Market is growing at an 19.35% CAGR, by rising diabetes prevalence, increasing demand for cost-effective insulin therapies, NHS cost-containment initiatives, and expanding biosimilar adoption.
United Kingdom Insulin Biosimilars Market Insights Forecasts to 2035
- The United Kingdom Insulin Biosimilars Market Size Was Estimated at USD 3.0 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 19.35% from 2025 to 2035
- The United Kingdom Insulin Biosimilars Market Size is Expected to Reach USD 17.6 Billion by 2035
Notable Insights for United Kingdom Insulin Biosimilars Market
- By product type, long-acting insulin biosimilars dominated, accounting for approximately 60% share in 2024, driven by widespread use in diabetes management and glycemic control.
- By diabetes type, Type 2 diabetes applications dominated, holding approximately 75% share, due to the large diabetic population requiring long-term insulin therapy.
- Approximately 7–8% of the UK population is living with diabetes, supporting increasing demand for affordable insulin biosimilar treatment options nationwide.
Download the eBook (ToC)
- Around 65% of insulin-treated patients in NHS settings are gradually transitioning toward biosimilar insulin therapies to improve healthcare cost efficiency and accessibility.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Insulin Biosimilars Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Insulin Biosimilars Market
- Biocon Biologics
- Viatris
- Eli Lilly and Company
- Novo Nordisk
- Sanofi
- Pfizer
- Wockhardt
- Gan & Lee Pharmaceuticals
- Julphar
- Others
Recent Developments:
- In February 2025: Samsung Bioepis continued expanding its endocrinology biosimilar pipeline and regulatory activities, supporting future insulin biosimilar availability and strengthening competition within the United Kingdom insulin biosimilars market.
- In March 2024: Biocon strengthened its insulin biosimilar pipeline and European supply capabilities, supporting broader availability of insulin glargine therapies and long-term growth in the United Kingdom insulin biosimilars market.
Market Segmentation:
United Kingdom Insulin Biosimilars Market, By Product Type
- Rapid-Acting Insulin Biosimilars
- Long-Acting Insulin Biosimilars
- Premixed Insulin Biosimilars
- Others
United Kingdom Insulin Biosimilars Market, By Indication
- Type 1 Diabetes
- Type 2 Diabetes
United Kingdom Insulin Biosimilars Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Diabetes Centers
United Kingdom Insulin Biosimilars Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
It is predicted that the UK Insulin Biosimilars Market will experience high growth on account of rising cases of diabetes, increased expenditure pressure on healthcare, and NHS funding of biosimilar uptake. It should be noted that the future growth potential of the market is based on the assumption that long-acting insulin biosimilars will continue to dominate the market owing to their efficacy in controlling glycemic balance and saving expenses on medication.